<DOC>
	<DOCNO>NCT01321723</DOCNO>
	<brief_summary>This study design provide information bone anabolic property absorption profile Unigene 's PTH Analog administer oral tablet period 24 week postmenopausal woman osteoporosis .</brief_summary>
	<brief_title>Pharmacodynamics , Pharmacokinetics , Safety Tolerability PTH Analog Tablets Postmenopausal Women</brief_title>
	<detailed_description>The choice 24-week treatment period base publish study PTH demonstrate potential produce statistically significant increase BMD patient postmenopausal osteoporosis within observation period .</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis , Postmenopausal</mesh_term>
	<mesh_term>Teriparatide</mesh_term>
	<mesh_term>Bone Density Conservation Agents</mesh_term>
	<criteria>Healthy postmenopausal woman ( 4580 year old ) diagnosis osteoporosis Use estrogen hormone replacement therapy Use bisphosphonates , strontium ranelate denosumab Use parathyroid analogue bone metabolic agent Medical condition might alter bone metabolism Any know clinically significant disease affect calcium metabolism history metabolic disorder include Paget 's disease , osteogenesis imperfecta , osteomalacia Impairment thyroid function</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Osteoporosis</keyword>
	<keyword>Bone Diseases , Metabolic</keyword>
	<keyword>Bone Diseases</keyword>
	<keyword>Bone Density Conservation Agents</keyword>
</DOC>